Add BrightSurf on Google Email

Baylor College of Medicine


Formate prevents most folic acid-resistant neural tube defects in mice

Researchers have discovered that formate supplementation can prevent most neural tube defects in mice that are resistant to folic acid treatment. The study found that disrupting formate synthesis was linked to the development of these defects, and that providing pregnant mice with extra formate could prevent them. These findings offer ...

SourceBaylor College of Medicine·JournalProceedings of the National Academy of Sciences·DateMay 1, 2018

Why is it harder for females to gain weight?

Researchers found that female POMC neurons fire faster than male's due to the expression of gene TAp63, leading to increased energy expenditure and protection against weight gain. This novel mechanism may facilitate future gender-specific therapeutic strategies for obesity and related disorders.

SourceBaylor College of Medicine·JournalNature Communications·DateApr 18, 2018

Scorpion venom component can reduce severity of rheumatoid arthritis

Researchers at Baylor College of Medicine discovered that a scorpion venom component, iberiotoxin, can specifically block the potassium channel in fibroblast-like synoviocytes, reducing rheumatoid arthritis severity. Treatment with iberiotoxin reversed joint damage and inflammation in rat models without inducing side effects.

SourceBaylor College of Medicine·JournalJournal of Pharmacology and Experimental Therapeutics·DateFeb 26, 2018

How Gata4 helps mend a broken heart

Researchers at Baylor College of Medicine found that Gata4 can reduce post-heart attack fibrosis, leading to improved cardiac function in small animal models. The study's results suggest a novel role for Gata4 in heart regeneration and may lead to new treatments for heart failure.

SourceBaylor College of Medicine·JournalJournal of Thoracic and Cardiovascular Surgery·DateAug 14, 2017

Clinical trial shows ready-to-use cells are safe and effective to treat viral infections

A clinical trial has demonstrated the safety and effectiveness of a new treatment using virus-specific cells to treat viral infections in patients who have received a hematopoietic stem cell transplant. The treatment resulted in an overall complete or partial response rate of 92% in patients with severe, drug-resistant viral infections.

SourceBaylor College of Medicine·JournalJournal of Clinical Oncology·DateAug 8, 2017